/* */ PELVIPHARM - SPECIALIZED PRECLINICAL EXPERTISE in male and female sexual functions and diseases of the lower urinary tract
Receive our news

 
NEWS

February 1st - 2024

Presentation at the ESSM 2024

Pelvipharm at the Congress of the ESSM (European Society for Sexual Medicine) in Bari, Italy, 8-10 February, 2024.

  • François Giuliano will present one abstract during the podium session entitled "Basic science": 

 "LIB-01, a novel promising oral drug under development for the treatment of erectile dysfunction (ED) – a summary of nonclinical studies".
F. Giuliano, D. Gorny, M. Razanakolona, D. Behr-Roussel, R. Assaly, C. Gauffin

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

ESSM_2024_1.jpg

September 12th - 2023

Presentation at the SMSNA 2023

Pelvipharm at the 24th Annual Fall Scientific Meeting in San Diego, USA, 16-19 November, 2023.
  • François Giuliano will present one abstract : 

"Overview of nonclinical studies of LIB-01, a novel promising oral drug under development for treatment of erectile dysfunction".

François Giuliano, Diane Gorny, Mahita Razanakolona, Delphine Behr-Roussel, Rana Assaly, Charlotta Gauffin

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

2023.San_Diego_Banners_website_1.jpg

October 2nd - 2023

Presentation at the ICS 2023

Presentation at the International Continence Society in Toronto, September 27th-29th, 2023.

  • Julien Ratelade from EG427 presented the results of a project performed in collaboration with Pelvipharm:

    " Intravesical administration of EG110A, a novel nonreplicative Herpes Simplex Virus (HSV-1)-derived vector expressing the light chain of botulinum toxin F, inhibits C-type fibers in an acute intravesical capsaicin rat model "
    Ratelade J1, Faugeroux J2, Behr-Roussel D2, Epstein A1, Denys P3, Giuliano F3, Haag-Molkenteller C1, Salot S1.
    1. EG427, 2. Pelvipharm, 3. Université Versailles Saint-Quentin/Paris Saclay/Faculty of Medicine, Neuro-uro-andrology R. Poincaré academic hospital/APHP, Garches, FRANCE
ICS_2023_Toronto_2.jpg



April 21st - 2023

Presentations at the WCE 2023

Pelvipharm at the 15th World Congress on Endometriosis in Edinburg, May 3rd-6th, 2023.

  • Delphine Behr-Roussel  will present :
    " Effect of estrous cycle stage on establishment of a endometriosis rodent model to evaluate the effect of new therapeutic strategies "
    R. Assaly, S. Compagnie, L. Allimonnier, M. Bracconi, F. Giuliano, L. Alexandre, D. Behr-Roussel.

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

15th World congress on endometriosis_3-6 MAy 2023_1.jpg

WCE2023_Edinburg.png

February 3rd - 2023

Presentation at the ESSM 2023

Pelvipharm at the Congress of the ESSM (European Society for Sexual Medicine) in Rotterdam, Netherlands, 16-18 February, 2023.

  • Mahita Razanakolona will present one abstract during the podium session entitled "Basic science": 

"The Pro-erectile facilitator effect of LIB-01 in anesthetized Wistar rats is likely mainly mediated via an NO/cGMP-independent pathway".
D. Gorny, M. Razanakolona, C. Gauffin, F. Giuliano, D. Behr-Roussel, R. Assaly.

  • Delphine Behr-Roussel will chair the podium session "Basic science" 

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

ESSM2023_728____90_px.png

May 5th - 2022

Presentations at the SEUD 2022


Pelvipharm will present oneabstracts during the session entitled "Basic science":
  • Rana Assaly  will present in poster session: "Establishment of a rodent model of endometriosis to evaluate the effect of new therapeutic strategies."
    S. Compagnie, M. Bracconi, P. Muthan, F. Giuliano, D. Behr-Roussel and R. Assaly.

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

SEUD_vignette_2022.jpg

Page 1 / 22     Previous      1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  Next 
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL